Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Treace Medical Concepts (TMCI) EBITDA (2020 - 2025)

Historic EBITDA for Treace Medical Concepts (TMCI) over the last 6 years, with Q3 2025 value amounting to -$16.3 million.

  • Treace Medical Concepts' EBITDA fell 734.33% to -$16.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$50.2 million, marking a year-over-year increase of 1792.46%. This contributed to the annual value of -$55.8 million for FY2024, which is 1311.79% down from last year.
  • According to the latest figures from Q3 2025, Treace Medical Concepts' EBITDA is -$16.3 million, which was down 734.33% from -$17.4 million recorded in Q2 2025.
  • In the past 5 years, Treace Medical Concepts' EBITDA registered a high of -$595000.0 during Q4 2024, and its lowest value of -$21.3 million during Q2 2024.
  • In the last 5 years, Treace Medical Concepts' EBITDA had a median value of -$12.4 million in 2023 and averaged -$11.3 million.
  • Its EBITDA has fluctuated over the past 5 years, first plummeted by 856666.67% in 2021, then soared by 9003.35% in 2024.
  • Over the past 5 years, Treace Medical Concepts' EBITDA (Quarter) stood at -$5.6 million in 2021, then increased by 20.69% to -$4.4 million in 2022, then plummeted by 34.49% to -$6.0 million in 2023, then soared by 90.03% to -$595000.0 in 2024, then plummeted by 2631.93% to -$16.3 million in 2025.
  • Its last three reported values are -$16.3 million in Q3 2025, -$17.4 million for Q2 2025, and -$16.0 million during Q1 2025.